腹膜透析治疗难治性充血性心力衰竭的临床应用

发布时间：2018-06-17 05:51

本文选题：腹膜透析治疗 + 肾功能不全　；参考：《上海医学》2017年01期

【摘要】：正难治性充血性心力衰竭的发病率高、病程迁延、预后差。利尿剂作为治疗难治性充血性心力衰竭一线药物,其作用有限。腹膜透析(PD)治疗难治性充血性心力衰竭能够有效控制容量,纠正电解质紊乱,治疗肾功能不全和改善心功能。与血液透析(HD)相比,PD治疗难治性充血性心力衰竭患者的生存率相同,且无需全身抗凝,血流动力学稳定,低血压发生风险较小,能够避免因使用中心静脉导管(CVC)导致的感染、血栓形成等并
[Abstract]:The incidence of refractory congestive heart failure is high, the course of disease is prolonged and the prognosis is poor. Diuretics as a first-line drug in the treatment of refractory congestive heart failure have limited effect. Peritoneal dialysis (PDD) for refractory congestive heart failure can effectively control volume, correct electrolyte disturbance, treat renal insufficiency and improve cardiac function. The survival rate of patients with refractory congestive heart failure was the same as that of patients with refractory congestive heart failure treated with hemodialysis (HD), without systemic anticoagulation, stable hemodynamics, low risk of hypotension, and the ability to avoid infection caused by the use of central venous catheter (CVC). Thrombosis, etc.
【作者单位】：交通大学医学院附属仁济医院肾脏科;
【基金】：上海市卫生和计划生育委员会中西医结合重点项目(ZHYY-ZXYJHZX-1-02) 国家自然科学基金(81573748)资助
【分类号】：R541.61

【相似文献】